The European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to Adverum Biotechnologies’ ADVM lead drug ADVM-022 for the treatment of wet age-related macular degeneration (wet AMD).
A Phase 2 study in wet AMD is planned to investigate ADVM-022, expects dosing the first patient in the third quarter of 2022.
Laurent Fischer, M.D., president and chief executive officer, said, “We are extremely pleased with EMA's decision to grant ADVM-022 PRIME designation. Following the encouraging results seen in the OPTIC trial in wet AMD, our PRIME designation recognizes the broad potential of ADVM-022 and is based in part on our trial subjects now having three-year sustained aflibercept expression with stable disease and maintained long-term central subfield thickness and visual acuity after a single IVT injection.”
PRIME is a program launched by the EMA to enhance support for research on and development of medicines that target a significant unmet medical need.
Adverum Shares are trading higher 2 percent at $1.11
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.